Analysts Expect ANI Pharmaceuticals to Announce $0.57 Earnings Per Share (NASDAQ:ANIP)

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $61.50 for the company and are forecasting that the company will post $0.57 earnings per share for the current quarter, according to Zacks. Zacks has also given ANI Pharmaceuticals an industry rank of 62 out of 265 based on the ratings given to its competitors.

ANI Pharmaceuticals (NASDAQ:ANIP) traded up 1.88% on Friday, hitting $57.45. 49,284 shares of the company’s stock traded hands. ANI Pharmaceuticals has a 1-year low of $18.52 and a 1-year high of $61.43. The stock has a 50-day moving average of $54.50 and a 200-day moving average of $36.90. The company has a market cap of $650.2 million and a price-to-earnings ratio of 53.60.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.20. The company had revenue of $17.40 million for the quarter, compared to the consensus estimate of $14.60 million. The company’s revenue for the quarter was up 123.1% on a year-over-year basis. Analysts expect that ANI Pharmaceuticals will post $1.37 EPS for the current fiscal year.

ANIP has been the subject of a number of recent research reports. Analysts at Guggenheim initiated coverage on shares of ANI Pharmaceuticals in a research note on Monday, December 15th. They set a “buy” rating and a $65.00 price target on the stock. Separately, analysts at Roth Capital raised their price target on shares of ANI Pharmaceuticals from $55.00 to $65.00 in a research note on Thursday, November 20th. They now have a “buy” rating on the stock. Finally, analysts at Zacks upgraded shares of ANI Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Thursday, November 6th. They now have a $46.90 price target on the stock.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

To get a free copy of the research report on ANI Pharmaceuticals (ANIP), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Instacart the Grocery Delivery Startup Raises $210 Million
Instacart the Grocery Delivery Startup Raises $210 Million
China Will Relax Regulations on Banks Renminbi Trading
China Will Relax Regulations on Banks Renminbi Trading
Subway in Safety Scandal in China over Food
Subway in Safety Scandal in China over Food
UPS and FedEx Make Improvements During Holiday Season
UPS and FedEx Make Improvements During Holiday Season
MasterCard Spending Report for Holidays Shows Weak Electronics
MasterCard Spending Report for Holidays Shows Weak Electronics
Gift Cards Have Become Hugely Popular, but Have Risks
Gift Cards Have Become Hugely Popular, but Have Risks


Leave a Reply

Advertisement
Advertisement
© 2006-2015 Leoncheng.